Revvity (RVTY) Gains Ahead Of Earnings, Is The Stock Too Expensive?

Revvity (RVTY) heads into its 3 November third quarter 2026 earnings date with investors focused on how AI tools and diagnostics are shaping results, following a sharp recent share price upswing.

The recent move sits on top of powerful momentum, with a 40.45% 3 month share price return and a 57.63% year to date share price gain. Total shareholder return of 65.04% over one year contrasts with a 5 year total shareholder return that remains 11.33% lower. This underscores how quickly sentiment toward Revvity has shifted as investors reassess growth potential and risk around AI tools and diagnostics.

Capture this earnings momentum theme by scanning a curated set of 94 AI infrastructure stocks that, like Revvity, are tied to the build out of data heavy AI and diagnostics platforms.

Revvity now trades above both its average analyst target and a discounted cash flow estimate, after a rapid re rating. Where does a reasonable fair value line actually fall in that spread?

Most Popular Narrative: 19% Overvalued

Revvity closed at $154.71, while the most followed narrative pegs fair value near $130.27. The debate is whether today’s premium fully reflects expectations for AI enabled workflows, software and diagnostics.

The current valuation suggests that investors are already paying a premium for sustained growth in areas such as Signals software, reproductive health, and ex-China immunodiagnostics, even though the company’s longer-term revenue and EPS trends have been under pressure.

See why 10 investors see Revvity as 19% overvalued.

Result: Fair Value of $130.27 (OVERVALUED)

Still, if Signals software returns to high teens reported growth, or reproductive health and ex China diagnostics keep outperforming, Revvity’s current premium could look less stretched.

Find out about the key risks to this Revvity narrative.

Next Steps

Sentiment around Revvity is sharply split, with strong enthusiasm balanced against clear concerns about future execution and valuation risk. Move quickly, review the underlying metrics yourself, and weigh both sides of the story by starting with the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Revvity?

Do not stop your research with Revvity. Cast the net wider with a few targeted stock lists so you can review opportunities across a broader range of companies.

• Target resilience by filtering for companies with strong finances using the list of solid balance sheet and fundamentals (25 results).
• Focus on value by scanning a curated pool of quality businesses trading at prices that may be of interest through the 33 high quality undervalued stocks.
• Look for potential early stage opportunities by reviewing the 13 elite penny stocks with strong financials while they are still less widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com